Literature DB >> 23684514

Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder.

Faith Dickerson1, Cassie Stallings, Andrea Origoni, Crystal Vaughan, Sunil Khushalani, Robert Yolken.   

Abstract

BACKGROUND: Some individuals with bipolar disorder have cognitive deficits even when euthymic. In previous studies, we found an association between elevated levels of C-reactive protein (CRP), a marker of inflammation, and reduced cognitive functioning in schizophrenia. This issue has not been examined in bipolar disorder.
METHODS: We measured the levels of high sensitivity CRP in serum samples from 107 individuals with bipolar disorder. Cognitive functioning was measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Trail Making Test Part A and WAIS Information and Letter Number Sequencing. We estimated the odds of RBANS scores <=70 for participants whose CRP levels were above the 75th and the 90th percentile of the level of non-psychiatric controls. We also examined the association between cognitive scores and CRP levels. Covariates included demographic factors, mood symptom severity, cigarette smoking status, and body mass index.
RESULTS: There was a significantly increased odds of low RBANS total score for individuals who had a CRP level higher than the 90th percentile (OR=4.32, p=.018) and the 75th percentile (OR=3.07, p=.04)) of the control group. There was an inverse relationship between CRP levels and performance on RBANS total (t=-2.48, p=.015); RBANS immediate memory (t=-2.16, p=.033); RBANS attention (t=-2.18, p=.032); RBANS language (t=-2.13, p=.036); Trail Making A (t=-2.39, p=.019). LIMITATIONS: Factors which we did not measure such as diet, allergen exposure, and underlying autoimmune disorders may contribute to CRP levels.
CONCLUSIONS: Inflammation may play a major role in the cognitive deficits associated with bipolar disorder.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; C-reactive protein; Cognitive; Herpes simplex virus type 1; Immune response; Inflammatory marker

Mesh:

Substances:

Year:  2013        PMID: 23684514     DOI: 10.1016/j.jad.2013.04.039

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  31 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 2.  Bipolar Depression and Cognitive Impairment: Shared Mechanisms and New Treatment Avenues.

Authors:  Colin A Depp; Sheena Dev; Lisa T Eyler
Journal:  Psychiatr Clin North Am       Date:  2015-12-11

3.  Allostatic load and reduced cortical thickness in schizophrenia.

Authors:  Joshua Chiappelli; Peter Kochunov; Anya Savransky; Feven Fisseha; Krista Wisner; Xiaoming Du; Laura M Rowland; L Elliot Hong
Journal:  Psychoneuroendocrinology       Date:  2016-11-24       Impact factor: 4.905

Review 4.  Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites.

Authors:  George Anderson; Michael Maes
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

5.  Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.

Authors:  G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-10       Impact factor: 5.270

Review 6.  Inflammatory mediators of cognitive impairment in bipolar disorder.

Authors:  Isabelle E Bauer; Michaela C Pascoe; Bianca Wollenhaupt-Aguiar; Flavio Kapczinski; Jair C Soares
Journal:  J Psychiatr Res       Date:  2014-05-02       Impact factor: 4.791

7.  Effect of Increased Neutrophil-to-Lymphocyte Ratio (NLR) and Decreased Mean Platelet Volume (MPV) Values on Inflammation in Acute Mania.

Authors:  Hasan Mayda; Ahmet Ahsen; Erman Bağcioğlu; Ahmet Öztürk; Bülent Bahçeci; Etem Soyuçok; Erol Başpinar; Memnune Sena Ulu
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

8.  High-Sensitive c-Reactive Protein Levels in Euthymic Bipolar Patients: Case-Control Study.

Authors:  Ghada Hamdi; Hanen Ben Ammar; Emira Khelifa; Arij Ben Chaaben; Sabria Khouadja; Fayza Ayari; Ons Mihoub; Ryad Tamouza; Fethi Guémira; Zouhaier Elhechmi
Journal:  Psychiatr Q       Date:  2020-10-22

9.  Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Authors:  Iris E Sommer; Roos van Westrhenen; Marieke J H Begemann; Lot D de Witte; Stefan Leucht; René S Kahn
Journal:  Schizophr Bull       Date:  2013-10-08       Impact factor: 9.306

10.  Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

Authors:  Ewa Bulzacka; Laurent Boyer; Franck Schürhoff; Ophélia Godin; Fabrice Berna; Lore Brunel; Méja Andrianarisoa; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chéreau-Boudet; Gabrielle Chesnoy-Servanin; Jean-Marie Danion; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Tifenn Le Gloahec; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Romain Rey; Raphaëlle Richieri; Christine Passerieux; Paul Roux; Hanan Yazbek; Marion Leboyer; Guillaume Fond
Journal:  Schizophr Bull       Date:  2016-05-03       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.